Pliant Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 0.851 USD (Nov 2, 2026, 9:46 AM EST) · Market cap 52.70M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company’s lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of αvß8 and αvß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics,...